{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:54:43Z","timestamp":1790895283664,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was supported by the Italian Ministry of Health\u2014Ricerca Corrente Annual Program 2026."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is characterized by transcriptional and metabolic heterogeneity, which influences its response to therapeutics. Epigenetic drugs such as Bromodomain and Extra-Terminal domain inhibitors (BETi) are no exception to this variable response. However, the determinants of BETi sensitivity and the underlying mechanisms of response remain poorly understood, particularly in the context of metabolic reprogramming. Here, we investigated the responses to the BETi JQ1 and OTX015 across a heterogeneous panel of TNBC models. We found that the susceptibility to BETi partially correlates with basal BRD4 protein levels, but only in contexts characterized by high baseline cMYC levels, where BETi treatment triggers an upregulation of glycolytic genes, an effect that is absent in models displaying an intrinsically glycolytic phenotype. While the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) is effective as a single agent in the glycolytic-prone setting, it has limited efficacy in other TNBC models. Strikingly, a notable additive effect is visible when BETi are combined with 2-DG, leading to significant apoptotic induction, specifically in the BETi-responsive cells, whereas this additive effect is not observed in the glycolysis-driven models. Mechanistically, we identified that BETi induces the HIF1\u03b1 transcriptional program in cMYC-high cells, which upregulates key glycolytic enzymes. HIF1\u03b1 depletion reduced this response, confirming that HIF1\u03b1 is functionally required for this adaptive rewiring. In conclusion, TNBC cells adapt to BETi by undergoing HIF1\u03b1-mediated metabolic rewiring towards glycolysis. This adaptive response creates a vulnerability, rendering these tumors sensitive to the combination of BET and glycolysis inhibitors. By mapping a transcriptional-metabolic axis that dictates BETi sensitivity, this study moves beyond the identification of a resistant subset of TNBC to reveal a deeper principle: targeted inhibition can actively reprogram cellular circuitry, thereby constructing its own unique therapeutic vulnerability. Thus, the path to overcoming resistance may lie not in evading this rewiring, but in strategically exploiting the alternative dependencies it creates.<\/jats:p>","DOI":"10.1038\/s41420-026-03230-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:44:01Z","timestamp":1783529041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BET inhibition unmasks a targetable glycolytic dependency through a HIF1\u03b1 stabilization and driven transcriptional program in a defined subset of triple-negative breast Cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-7197","authenticated-orcid":false,"given":"Teresa","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Pisanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Torricelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-2075","authenticated-orcid":false,"given":"Alessia","family":"Ciarrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1219-0038","authenticated-orcid":false,"given":"Mariaelena","family":"Pistoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3230_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3230_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"3230_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"3230_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5306\/wjco.v7.i1.122","volume":"7","author":"JP Long","year":"2016","unstructured":"Long JP. Targeting metabolism in breast cancer: How far we can go? WJCO. 2016;7:122.","journal-title":"WJCO"},{"key":"3230_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"},{"key":"3230_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0434-6","volume":"16","author":"H Pelicano","year":"2014","unstructured":"Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 2014;16:434.","journal-title":"Breast Cancer Res"},{"key":"3230_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000339513","volume":"80","author":"J Choi","year":"2013","unstructured":"Choi J, Jung WH, Koo JS. Metabolism-Related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology. 2013;80:41\u201352.","journal-title":"Pathobiology"},{"key":"3230_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40170-017-0168-x","volume":"5","author":"NJ Lanning","year":"2017","unstructured":"Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, et al. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab. 2017;5:6.","journal-title":"Cancer Metab"},{"key":"3230_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s42003-021-02805-8","volume":"4","author":"N Shen","year":"2021","unstructured":"Shen N, Korm S, Karantanos T, Li D, Zhang X, Ritou E, et al. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. Commun Biol. 2021;4:1289.","journal-title":"Commun Biol"},{"key":"3230_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060495","volume":"12","author":"S Liu","year":"2023","unstructured":"Liu S, Li Y, Yuan M, Song Q, Liu M. Correlation between the Warburg effect and progression of triple-negative breast cancer. Front Oncol. 2023;12:1060495.","journal-title":"Front Oncol"},{"key":"3230_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1126913","volume":"12","author":"B Kaur","year":"2023","unstructured":"Kaur B, Sohrabi Y, Achreja A, Lisanti MP, Martinez-Outschoorn UE. Editorial: Hallmark of cancer: Reprogramming of cellular metabolism. Front Oncol. 2023;12:1126913.","journal-title":"Front Oncol"},{"key":"3230_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","volume":"33","author":"C Sun","year":"2018","unstructured":"Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33:401\u201316.e8.","journal-title":"Cancer Cell"},{"key":"3230_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2021","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of Bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharm. 2021;11:621093.","journal-title":"Front Pharm"},{"key":"3230_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413\u20137.","journal-title":"Nature"},{"key":"3230_CR15","doi-asserted-by":"publisher","first-page":"e0200826","DOI":"10.1371\/journal.pone.0200826","volume":"13","author":"GW Rhyasen","year":"2018","unstructured":"Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, et al. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. Asselin E, editor. PLoS ONE. 2018;13:e0200826.","journal-title":"PLoS ONE"},{"key":"3230_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/1541-7786.MCR-17-0568","volume":"16","author":"GP Andrieu","year":"2018","unstructured":"Andrieu GP, Denis GV. BET proteins exhibit transcriptional and functional opposition in the epithelial-to-mesenchymal transition. Mol Cancer Res. 2018;16:580\u20136.","journal-title":"Mol Cancer Res"},{"key":"3230_CR17","doi-asserted-by":"publisher","first-page":"53997","DOI":"10.18632\/oncotarget.9804","volume":"7","author":"V Sahai","year":"2016","unstructured":"Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Targeting BET bromodomain proteins in solid tumors. Oncotarget. 2016;7:53997\u20134009.","journal-title":"Oncotarget"},{"key":"3230_CR18","doi-asserted-by":"publisher","first-page":"23756","DOI":"10.1074\/jbc.M116.738666","volume":"291","author":"JM Sahni","year":"2016","unstructured":"Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, et al. Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of Aurora Kinases. J Biol Chem. 2016;291:23756\u201368.","journal-title":"J Biol Chem"},{"key":"3230_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2019.05.004","volume":"30","author":"G Civenni","year":"2019","unstructured":"Civenni G, Bosotti R, Timpanaro A, V\u00e0zquez R, Merulla J, Pandit S, et al. Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer. Cell Metab. 2019;30:303\u201318.e6.","journal-title":"Cell Metab"},{"key":"3230_CR20","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1111\/cas.15061","volume":"112","author":"L Li","year":"2021","unstructured":"Li L, Meng Y, Wu X, Li J, Sun Y. Bromodomain-containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics. Cancer Sci. 2021;112:4013\u201325.","journal-title":"Cancer Sci"},{"key":"3230_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111304","volume":"40","author":"G Yan","year":"2022","unstructured":"Yan G, Luna A, Wang H, Bozorgui B, Li X, Sanchez M, et al. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Rep. 2022;40:111304.","journal-title":"Cell Rep"},{"key":"3230_CR22","doi-asserted-by":"crossref","unstructured":"Yang G, Zhou D, Li J, Wang W, Zhong W, Fan W, et al. VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer. Oncol Lett. 2019;18:2340\u20137.","DOI":"10.3892\/ol.2019.10534"},{"key":"3230_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13730","volume":"57","author":"T Rossi","year":"2024","unstructured":"Rossi T, Iorio E, Chirico M, Pisanu ME, Amodio N, Cantafio MEG, et al. BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells. Cell Prolif. 2024;57:e13730.","journal-title":"Cell Prolif"},{"key":"3230_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13046-022-02571-3","volume":"42","author":"T Rossi","year":"2023","unstructured":"Rossi T, Zamponi R, Chirico M, Pisanu ME, Iorio E, Torricelli F, et al. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells. J Exp Clin Cancer Res. 2023;42:7.","journal-title":"J Exp Clin Cancer Res"},{"key":"3230_CR25","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"3230_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.","journal-title":"Breast Cancer Res"},{"key":"3230_CR27","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/life13122311","volume":"13","author":"BL Witt","year":"2023","unstructured":"Witt BL, Tollefsbol TO. Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life. 2023;13:2311.","journal-title":"Life"},{"key":"3230_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2014.09.003","volume":"355","author":"D Zhang","year":"2014","unstructured":"Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014;355:176\u201383.","journal-title":"Cancer Lett"},{"key":"3230_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.bjc.6600547","volume":"87","author":"RL Aft","year":"2002","unstructured":"Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer. 2002;87:805\u201312.","journal-title":"Br J Cancer"},{"key":"3230_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1541-7786.MCR-19-0842","volume":"18","author":"C Lu","year":"2020","unstructured":"Lu C, Ren C, Yang T, Sun Y, Qiao P, Wang D, et al. A noncanonical role of Fructose-1, 6-Bisphosphatase 1 is essential for inhibition of Notch1 in breast cancer. Mol Cancer Res. 2020;18:787\u201396.","journal-title":"Mol Cancer Res"},{"key":"3230_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12672-025-02112-2","volume":"16","author":"M Wang","year":"2025","unstructured":"Wang M, Huang X, Zhang D, Liu Y, Liu P. The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance. Discov Onc. 2025;16:346.","journal-title":"Discov Onc"},{"key":"3230_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.139273","volume":"293","author":"Q Song","year":"2025","unstructured":"Song Q, Sui J, Yang Y, Zhang H, Ya L, Yang L. Fructose-1,6-bisphosphatase 1 in cancer: Dual roles, mechanistic insights, and therapeutic potential \u2013 A comprehensive review. Int J Biol Macromol. 2025;293:139273.","journal-title":"Int J Biol Macromol"},{"key":"3230_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06014-9","volume":"23","author":"G Zhao","year":"2025","unstructured":"Zhao G, Liu Y, Yin S, Cao R, Zhao Q, Fu Y, et al. FOSL1 transcriptionally dictates the Warburg effect and enhances chemoresistance in triple-negative breast cancer. J Transl Med. 2025;23:1.","journal-title":"J Transl Med"},{"key":"3230_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41420-025-02714-3","volume":"11","author":"Z Ge","year":"2025","unstructured":"Ge Z, Wallace M, Turner R, Yin M, Rooney MF, Porter RK. Metabolic interplay between exogenous cystine and glutamine dependence in triple-negative breast cancer. Cell Death Discov. 2025;11:430.","journal-title":"Cell Death Discov"},{"key":"3230_CR35","doi-asserted-by":"publisher","first-page":"12074","DOI":"10.3390\/ijms232012074","volume":"23","author":"AR Estrada-P\u00e9rez","year":"2022","unstructured":"Estrada-P\u00e9rez AR, Bakalara N, Garc\u00eda-V\u00e1zquez JB, Rosales-Hern\u00e1ndez MC, Fern\u00e1ndez-Pomares C, Correa-Basurto J. LC\u2013MS based lipidomics depict Phosphatidylethanolamine as biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 cells. IJMS. 2022;23:12074.","journal-title":"IJMS"},{"key":"3230_CR36","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10147-025-02916-w","volume":"30","author":"J Li","year":"2025","unstructured":"Li J, Velaga R, Takano Y, Masuda N. Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers. Int J Clin Oncol. 2025;30:2399\u2013409.","journal-title":"Int J Clin Oncol"},{"key":"3230_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022;32:477\u201390.","journal-title":"Cell Res"},{"key":"3230_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39789-9","volume":"9","author":"S O\u2019Neill","year":"2019","unstructured":"O\u2019Neill S, Porter RK, McNamee N, Martinez VG, O\u2019Driscoll L. 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype. Sci Rep. 2019;9:3788.","journal-title":"Sci Rep"},{"key":"3230_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114213","volume":"182","author":"C Laussel","year":"2020","unstructured":"Laussel C, L\u00e9on S. Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms. Biochem Pharmacol. 2020;182:114213.","journal-title":"Biochem Pharmacol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03230-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03230-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03230-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:16Z","timestamp":1790892136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03230-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3230"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03230-8","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"395"}}